KK3910

Phase 1Small molecule

Kyowa Kirin Co., Ltd.

KK3910 is one of 27 small molecule programs targeting Essential Hypertension. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionRecruiting

Essential HypertensionPhase 1

Recruiting

Competition

Competitive Landscape

51 competitors in Essential Hypertension

#DrugCompanyPhaseTrials

Zebeta

Teva

Approved

4 2

Tekturna

Tibotec Pharmaceuticals, Ireland

Approved

10 3

Bayer Aspirin

Bayer

Approved

1 4

Aldactone

Rifadin

Cialis

Cardura

VViatris Specialty LLC

Approved

1 8

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 9

Coreg

Nizoral

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Study completion

NCT06823947

Clinical

Trials by Indication[1]

Unspecified1 trial

A Phase 1, Placebo-Controlled, Double-Blind, Randomized, Single and Multiple Ascending-Dose Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension

Recruiting· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 1·NCT06823947·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KK3910. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KK3910 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KK3910. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kyowa Kirin Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Kyowa Kirin Co., Ltd.

KK3910

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News